mannitol has been researched along with eplerenone in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Chi, JF; Guo, HY; Lee, JD; Ueda, T; Uzui, H | 1 |
| Balogh, DB; Fekete, A; Genovese, F; Hodrea, J; Hosszu, A; Koszegi, S; Lakat, T; Lenart, L; Molnar, A; Sparding, N; Szabo, AJ; Szkibinszkij, E; Vannay, A; Wagner, L | 1 |
1 review(s) available for mannitol and eplerenone
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
2 other study(ies) available for mannitol and eplerenone
| Article | Year |
|---|---|
Effects of eplerenone on the activation of matrix metalloproteinase-2 stimulated by high glucose and interleukin-1β in human cardiac fibroblasts.
Topics: Cell Line; Culture Media; Enzyme Activation; Eplerenone; Fibroblasts; Gelatinases; Gene Expression; Glucose; Humans; Interleukin-1beta; Mannitol; Matrix Metalloproteinase 2; Myocardium; Osmolar Concentration; RNA, Messenger; Spironolactone | 2014 |
RAAS inhibitors directly reduce diabetes-induced renal fibrosis via growth factor inhibition.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Cell Line; Connective Tissue Growth Factor; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Epithelial Cells; Eplerenone; Fibroblasts; Fibrosis; Humans; Kidney; Losartan; Male; Mannitol; Mineralocorticoid Receptor Antagonists; Proto-Oncogene Proteins c-sis; Ramipril; Rats, Wistar; Renin-Angiotensin System; Spironolactone | 2019 |